home / stock / ensc / ensc news

ENSC News and Press, Ensysce Biosciences Inc.

Stock Information
Company Name: Ensysce Biosciences Inc.
Stock Symbol: ENSC
Market: NASDAQ
Website: ensysce.com
Menu
ENSC ENSC Quote ENSC Short ENSC News ENSC Articles ENSC Message Board
Get ENSC Alerts

News, Short Squeeze, Breakout and More Instantly...
ENSC - Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...
ENSC - Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain r...

ENSC - Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

~ Collaboration with Purisys Positions Ensysce to Expedite Lead OUD Candidate, PF9001, to IND Studies ~ SAN DIEGO, CA / ACCESSWIRE / June 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions ...

ENSC - Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

~ Selects Lead Candidate with Abuse Deterrence and Improved Safety Profile to Treat Opioid Use Disorder ~ SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions...
ENSC - Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

~ Geoff Birkett, Chief Commercial Officer, Invited to Serve on the Opening Panel at the EPHMRA 2024 Annual Conference ~ SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innova...

ENSC - Ensysce Biosciences regains Nasdaq compliance

2024-05-28 08:48:18 ET More on Ensysce Biosciences Ensysce Biosciences reports Q4 results Read the full article on Seeking Alpha For further details see: Ensysce Biosciences regains Nasdaq compliance

ENSC - Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutio...
ENSC - Ensysce Biosciences GAAP EPS of -$0.55

2024-05-13 09:16:56 ET More on Ensysce Biosciences Ensysce Biosciences reports Q4 results Seeking Alpha’s Quant Rating on Ensysce Biosciences Historical earnings data for Ensysce Biosciences Financial information for Ensysce Biosciences Read ...

ENSC - Ensysce Biosciences Reports First Quarter 2024 Financial Results

PF614's Phase 3 Clinical Plans Affirm the Path to Regulatory Approval FDA Breakthrough Therapy Designation of PF614-MPAR Expedites Clinical Program SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmac...

ENSC - Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

~ Dr. Kirkpatrick Leads the Company's Unique Response to Effectively Reduce Prescription Drug Overdose and Abuse ~ SAN DIEGO, CA / ACCESSWIRE / April 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative...
Next 10